辅助试剂

联系我们CONTACT US

  • 172 6727 7467
    24小时服务热线
  • 销售邮箱

双标多重免疫荧光试剂盒(石蜡切片)

一键复制产品信息

货号:AWI0692

价格: ¥700

规格: 20T 100T

  • 产品概述
  • 产品介绍

    酪酰胺信号放大技术(Tyramide Signal Amplification, TSA)主要是利用酪胺的过氧化物酶反应。酪胺非活性荧光素底物在HRP和过氧化氢的作用下,会被激活产生活化荧光底物,同时形成共价键结合位点,共价结合在蛋白抗原表面或附近的酪氨酸残基上,抗原和抗体的结合部位就会有大量的酪胺荧光素沉积,使抗原位点处的荧光信号增强。

    酪胺荧光素底物-抗原酪氨酸共价稳定结合,故TSA信号不会受微波影响,可用热修复法清除第一轮与抗原非共价结合的抗体复合物(冰冻切片,细胞爬片样本请试用抗体洗脱液洗脱法清除),并能在抗体去除后保留与抗原相关的荧光信号。然后,再用第二种一抗进行第二轮孵育,同时更换另一种酪胺荧光素底物,多次循环反复,不同的酪胺荧光素进行标记就可实现多重免疫组化染色。


    WPS图片(1).png


    TSA原理示意图

    产品组成成分

    单标双色

    10T

    50T

    100T

    保存条件

    TSA单标荧光染料

    0.5 ml

    2.5 ml

    5 ml

    -20℃,避光

    内源性过氧化物酶阻断剂

    0.5 ml

    2.5 ml

    5 ml

    4℃,避光

    超敏酶标山羊抗小鼠/IgG 聚合物

    0.5 ml

    2.5 ml

    5 ml

    4℃,避光

     

    双标三色

    20T

    100T

    保存条件

    TSA-520 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-570 荧光染料

    1 ml

    5 ml

    -20℃,避光

    抗体洗脱液(仅冰冻切片、细胞爬片有)

    6 ml

    30 ml

    RT

    内源性过氧化物酶阻断剂

    4 ml

    15 ml

    4℃,避光

    超敏酶标山羊抗小鼠/IgG 聚合物

    2 ml

    10 ml

    4℃,避光

     

    三标四色

    20T

    100T

    保存条件

    TSA-520 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-570 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-690 荧光染料

    1 ml

    5 ml

    -20℃,避光

    抗体洗脱液(仅冰冻切片、细胞爬片有)

    6 ml

    30 ml

    RT

    内源性过氧化物酶阻断剂

    5 ml

    25 ml

    4℃,避光

    超敏酶标山羊抗小鼠/IgG 聚合物

    3 ml

    15 ml

    4℃,避光

     

    四标五色

    20T

    100T

    保存条件

    TSA-520 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-570 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-620 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-690 荧光染料

    1 ml

    5 ml

    -20℃,避光

    抗体洗脱液(仅冰冻切片、细胞爬片有)

    6 ml

    30 ml

    RT

    内源性过氧化物酶阻断剂

    6 ml

    30 ml

    4℃,避光

    超敏酶标山羊抗小鼠/IgG 聚合物

    4 ml

    20ml

    4℃,避光

     

    五标六色

    20T

    100T

    保存条件

    TSA-520 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-570 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-620 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-690 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-780 荧光染料

    1 ml

    5 ml

    -20℃,避光

    抗体洗脱液(仅冰冻切片、细胞爬片有)

    6 ml

    30 ml

    RT

    内源性过氧化物酶阻断剂

    8 ml

    35 ml

    4℃,避光

    超敏酶标山羊抗小鼠/IgG 聚合物

    5 ml

    25 ml

    4℃,避光

     

    六标七色

    20T

    100T

    保存条件

    TSA-480 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-520 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-570 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-620 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-690 荧光染料

    1 ml

    5 ml

    -20℃,避光

    TSA-780 荧光染料

    1 ml

    5 ml

    -20℃,避光

    抗体洗脱液(仅冰冻切片、细胞爬片有)

    6 ml

    30 ml

    RT

    内源性过氧化物酶阻断剂

    10 ml

    45ml

    4℃,避光

    超敏酶标山羊抗小鼠/IgG 聚合物

    6 ml

    30 ml

    4℃,避光


    保存条件

    1、荧光染料(TSA-480/520/570/620/690/780): -20避光保存12个月

    2内源性过氧化物酶阻断剂、超敏酶标山羊抗小鼠/IgG 聚合物 :4℃避光保存,有效期 12 个月。

    3抗体洗脱液 RT保存,有效期 12 个月。


    实验前材料准备

      1、石蜡或冰冻切片,细胞爬片。建议配合 Abiowell 带有 IF-T 应用的一抗使用。

        石蜡切片:建议一抗应用中注明 IHC-P/IF-T;

        冰冻切片:建议一抗应用中注明 IHC-F/IF-T;

        细胞爬片:建议一抗应用中注明 IF/ICC/IF-C;

      2、缓冲液与修复液:PBS 缓冲液(货号:AWC0215)、柠檬酸钠抗原修复液(货号:AWI0206)(或其他适配修复液)。

      3、DAPI 染色液(推荐浓度:5μg/mL 货号:AWC0293)

      4、其他辅助材料:组化笔、避光湿盒、慢速摇床、抗荧光淬灭封片剂(货号:AWI0197)等。

      5、封闭山羊血清(货号:AWI0115)

    操作步骤

    (一)操作前注意事项

    1、TSA 染色灵敏度高于常规的荧光显色,建议开展正式实验前,进行单色预实验,选择最适合的一抗稀释比例;

    2、在进行多重染色时,通常建议先标记预实验中阳性丰度低的抗体。

    3、针对四标染色,推荐的染色顺序为:TSA-520 → TSA-570 → TSA-690 → TSA-620。

    4、由于 TSA-570 与 TSA-620 染料的发射波长较为接近,使用宽带通成像设备易出现信号串色,若需同时使用,需注意:

    *建议将 TSA-570 与 TSA-620 搭配弱阳性一抗使用;

    *尽量避免将其用于同一细胞中共同表达的靶标(例如 CD3 与 CD4 的共染组合);

    *图像采集时,请务必使用配备窄带通滤光片的成像设备,以有效区分相邻通道信号,确保成像质量。

    5、加入荧光染料及后续步骤需进行避光操作。

    6、操作过程中需保持载玻片组织的湿润,如出现干片情况,会导致非特异性的染色结果。

    7、持续加热修复的过程中,只需中小火维持沸腾,切勿高火加热让容器内试剂蒸发导致干片,且高火易导致组织脱片。

    8、使用小鼠组织实验时,建议选用兔源一抗搭配 HRP 标记的抗兔二抗,可减少非特异性染色。

    9、对富含脂肪的组织(如肝脏、乳腺等)染色时,建议在第 11  DAPI 染色前增加苏丹黑处理步骤,可有效消除脂肪的自发荧光及非特异性着色,避免干扰目标抗原信号检测,提升目标信号清晰度与检测准确性。

    (二)石蜡切片操作步骤(四标为例)

    1、脱蜡复水:

    (1)将石蜡玻片在 60 ℃ 烘烤 1-2 小时。

    (2)依次将切片放入二甲苯Ⅰ 15 分钟→二甲苯Ⅱ 15 分钟→二甲苯Ⅱ 15 分钟→无水乙醇Ⅰ 10分钟→无水乙醇Ⅱ 10分钟→ 95% 乙醇 5 分钟→ 85% 乙醇 5 分钟→ 75% 乙醇 5 分钟→蒸馏水洗。

    2、抗原修复:

    (1)向容器中加入约 2/3 体积的柠檬酸修复液或 EDTA 修复液,加盖后用微波炉高火加热至沸腾(修复液及条件需根据组织、抗原类型调整);

    (2)取出容器,待液体停止沸腾后,将切片间隔插入切片架并放入容器;

    (3)容器放回微波炉,低火加热 20 分钟,加热结束后在微波炉内静置 20 分钟后,取出自然冷却;

    (4)将玻片转移至 PH7.4 的 PBS 中,用慢速摇床洗涤 3 次,每次 5 分钟;

    (5)擦干组织周围水分(保持组织湿润),用组化笔在组织周围画封闭圈。

    3、内源性过氧化物酶阻断:

    向组织滴加内源性过氧化物酶阻断剂,在湿盒内室温孵育 10-15 分钟;随后将切片放入 PBS中,用慢速摇床洗涤 3 次,每次 3 分钟。

    4、封闭:

       用正常山羊血清均匀覆盖组织,室温封闭30min。

    5、一抗孵育:

    沥干玻片(约几秒),稀释一抗后滴加至完全覆盖组织;室温或 37 ℃ 孵育 3-4 小时,或 4 ℃ 湿盒过夜后 37 ℃ 复温 1-2 小时;最后用 PBST 冲洗 3 次,每次 2分钟。

    6、二抗孵育:

    沥干玻片,滴加 50-100μ超敏酶标山羊抗小鼠/兔 IgG聚合物(以覆盖组织为宜),室温孵育 30 分钟;用 PBST 冲洗 3 次,每次 2 分钟。

    7、TSA 反应:

    再次沥干玻片,滴加 50-100μL TSA-520 荧光染料(覆盖组织即可),孵育 5-15 分钟;PBST冲洗 3 次,每次 2分钟。

    8、抗体洗脱:

    将切片间隔插入切片架,放入含煮沸修复液的容器(煮沸修复液需能没过组织);微波炉低火加热 20 分钟后,在微波炉内静置 20 分钟,取出自然冷却;玻片转移至 PH7.4  PBS 中,慢速摇床洗涤 3 次,每次 5 分钟。

    9、第二轮染色:

    重复步骤 4-8,一抗更换为第二种目标一抗,TSA荧光染料换为 TSA-570。

    10、第三轮染色:

    重复步骤 4-8,一抗更换为第三种目标一抗,TSA荧光染料换为 TSA-690。

    11、第四轮染色:

    重复步骤 4-7(无需抗体洗脱),一抗更换为第四种目标一抗,TSA荧光染料换为 TSA-620。

    (注:多重免疫荧光染色的最后一轮均无需抗体洗脱)

    12、DAPI 复染细胞核:

    将玻片放入 PH7.4  PBS 中,慢速摇床洗涤 3 次,每次 5分钟;稍甩干后,向封闭圈内滴加DAPI 染液,避光室温孵育 10 分钟。

    13、封片:

    PBS 洗涤 3 次,每次 5 分钟;稍甩干切片,用抗荧光淬灭封片剂封片。

    14、镜检拍照:

    在荧光显微镜、共聚焦显微镜、多通道荧光扫描仪或多光谱成像系统下观察并采集图像。

     

    (三)细胞爬片/冰冻切片使用步骤(四标为例)

    1、固定(选做):

    冰冻切片:复温至室温后,滴加 4% 多聚甲醛(试剂盒未提供)孵育 10-15 分钟,室温晾干后用 PBS 浸泡脱胶(3 缸,每缸 10 分钟);若 OCT 包埋前未固定,建议必做此步骤。

    细胞爬片:直接加入 4% 多聚甲醛固定 10-15 分钟,PBS 洗涤 3 次,每次 5 分钟。

    2、破膜(选做):

    用 0.1-0.3% Triton X-100(需自备,浓度不建议超过 0.3%)室温通透 20 分钟;免疫原在胞外段的一抗可省略此步骤;后续用 PBS 洗涤 3 次,每次 5 分钟。

    3、内源性过氧化物酶阻断:

    (1)擦干组织周围水分(保持组织湿润),用组化笔在组织周围画封闭圈。

    (2)向组织滴加内源性过氧化物酶阻断剂,在湿盒内室温孵育 10-15 分钟;随后将切片放入PBS中,用慢速摇床洗涤 3 次,每次 3 分钟。

    4、封闭:

     用正常山羊血清均匀覆盖组织,室温封闭30min。

    5、一抗孵育:

    沥干玻片(约几秒),稀释一抗后滴加至完全覆盖组织;室温或 37 ℃ 孵育 3-4 小时,或 4 ℃ 湿盒过夜后 37 ℃ 复温 1-2 小时;最后用 PBST 冲洗 3 次,每次 2 分钟。

    6、二抗孵育:

    沥干玻片,滴加 50-100μL 超敏酶标山羊抗小鼠/兔 IgG聚合物(以覆盖组织为宜),室温孵育 30 分钟;用 PBST 冲洗 3 次,每次 2 分钟。

    7TSA 反应:

    滴加 50-100μL TSA-520 荧光染料(覆盖组织即可),孵育 5-15 分钟 PBST 冲洗 3 次,每次 2 分钟。

    8、抗体洗脱:

    滴加适量 37 ℃ 预热的抗体洗脱液覆盖组织,37 ℃ 放置 5-20 分钟,甩干后无需洗涤,再次滴加适量抗体洗脱液覆盖组织 37 ℃ 放置 5-20 分钟(通常两次洗脱合计20分钟),PBST 洗三次,每次 5 分钟。

    9、第二轮染色:

    重复步骤 4-8,一抗更换为第二种目标一抗,TSA荧光染料换为 TSA-570。

    10、第三轮染色:

    重复步骤 4-8,一抗更换为第三种目标一抗,TSA荧光染料换为 TSA-690。

    11、第四轮染色:

    重复步骤 4-7(无需抗体洗脱),一抗更换为第四种目标一抗,TSA荧光染料换为 TSA-620。

    (注:多重免疫荧光染色的最后一轮均无需抗体洗脱)

    12DAPI 复染细胞核:

    将玻片放入 PH7.4  PBS 中,慢速摇床洗涤 3 次,每次 5分钟;稍甩干后,向封闭圈内滴加 DAPI 染液,避光室温孵育 10 分钟。

    13、封片:

    PBS 洗涤 3 次,每次 5 分钟;稍甩干切片,用抗荧光淬灭封片剂封片。

    14、镜检拍照:

    在荧光显微镜、共聚焦显微镜、多通道荧光扫描仪或多光谱成像系统下观察并采集图像



    荧光染料参数表:

    染料

    激发波长

    发射波长

    荧光强度

    DAPI

    350nm

    420nm

    -

    TSA-480

    450nm

    480nm

    +

    TSA-520

    490nm

    520nm

    ++

    TSA-570

    550nm

    570nm

    +++

    TSA-620

    590nm

    620nm

    +

    TSA-690

    630nm

    690nm

    +++

    TSA-780

    750nm

    780nm

    ++++


    常见问题

     1、染色过深:一抗浓度过高,时间过长;TSA孵育时间过长,导致非特异性结合。

    2染色过浅或无染色:一抗浓度过低,时间过短;抗原修复不够;HRP是否失效。

    3无特异性染色:切片脱蜡不彻底。可适当延长烤片时间。

    4、有明显串色现象:上一支一抗未洗脱干净。

    5、抗体洗脱液使用三轮及以上易致组织 细胞核损伤,为降低核破碎风险,前两轮染色后的一抗洗脱可采用以下方法:将切片间隔置于切片架,浸入 50-60 ℃热水中浸泡 5-20 分钟,重复 2-3 次;若一抗残留未净,可少量使用抗体洗脱液并缩短孵育时长。第三轮开始使用抗体洗脱液正常洗脱。

     

    注意事项

    1、试剂初次使用前请置于4℃解冻,解冻后于4℃短期保存,避免反复冻融,请尽快使用。

    2为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。

        3本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品


    相关产品

    货号

    名称

    AWI0709

    荧光单标信号放大试剂(TSA-480)

    AWI0688

    荧光单标信号放大试剂(TSA-520)

    AWI0689

    荧光单标信号放大试剂(TSA-570)

    AWI0690

    荧光单标信号放大试剂(TSA-620)

    AWI0691

    荧光单标信号放大试剂(TSA-690)

    AWI0708

    荧光单标信号放大试剂(TSA-780)



    AWI0692

    双标多重免疫荧光试剂盒(石蜡切片)

    AWI0693

    三标多重免疫荧光试剂盒(石蜡切片)

    AWI0694

    四标多重免疫荧光试剂盒(石蜡切片)

    AWI0695

    五标多重免疫荧光试剂盒(石蜡切片)

    AWI0696

    六标多重免疫荧光试剂盒(石蜡切片)



    AWI0697

    双标多重免疫荧光试剂盒(冰冻切片)

    AWI0698

    三标多重免疫荧光试剂盒(冰冻切片)

    AWI0699

    四标多重免疫荧光试剂盒(冰冻切片)

    AWI0700

    五标多重免疫荧光试剂盒(冰冻切片)

    AWI0701

    六标多重免疫荧光试剂盒(冰冻切片)



    AWI0702

    双标多重免疫荧光试剂盒(细胞爬片)

    AWI0703

    三标多重免疫荧光试剂盒(细胞爬片)

    AWI0704

    四标多重免疫荧光试剂盒(细胞爬片)

    AWI0705

    五标多重免疫荧光试剂盒(细胞爬片)

    AWI0706

    六标多重免疫荧光试剂盒(细胞爬片)



    AWC0293

    DAPI染色液(5 μg/mL)

    AWC0215

    磷酸缓冲盐溶液(1×PBS,无钙镁)

    AWI0206

    柠檬酸钠抗原修复液(50×)

    AWI0117

    EDTA抗原修复液

    AWI0197

    抗荧光淬灭封片剂

    AWI0603

    免疫染色通透液(Triton X-100)



    参考文献 (8)

    International Journal of Biological Sciences IF:8.2

    Increasing evidence suggests that the mononuclear/macrophage system is vital in amplifying the inflammatory cascade in IgA Nephropathy (IgAN). However, the pathogenic mechanism of macrophages in IgAN and targeted treatment strategies still need to be explored. This study found that botanical triterpene celastrol (CLT) effectively alleviated renal lesions, M1-like macrophage infiltration, inflammatory factors production, and improved renal function in IgAN mice. We found that the renal macrophages of IgAN patients had high expression of ECM1, a crucial molecule involved in macrophage inflammatory polarization, positively correlated with the IgAN clinical severity. In murine macrophage Raw 264.7 cells, CLT inhibited macrophage M1-like polarization and the output of TNF-α and IL-6 by downregulating the ECM1/STAT5 pathway. Mechanistically, molecular docking, CESTA, and immunoprecipitation verified that CLT directly bound to ECM1 and increased the ubiquitination of ECM1. Collectively, these results illustrated that CLT inhibited proinflammatory macrophage in IgAN by directly targeting ECM1 to promote ubiquitination degradation of ECM1. Therefore, this study may provide a theoretical basis for exploring the pathogenesis of IgAN and identifying new perspectives for targeted therapy of IgAN.

    AGING CELL IF:7.1

    Renal proximal tubular epithelial cell (PTEC) senescence and defective autophagy contribute to kidney aging, but the mechanisms remain unclear. Caveolin-1 (CAV1), a crucial component of cell membrane caveolae, regulates autophagy and is associated with cellular senescence. However, its specific role in kidney aging is poorly understood. In this study, we generated Cav1 gene knockout mice and induced kidney aging using D-galactose (D-gal). The results showed that CAV1 expression increased in the renal cortex of the aging mice, which was accompanied by exacerbated renal interstitial fibrosis, elevated levels of senescence-associated proteins γH2AX and p16 INK4a , and increased β-galactosidase activity. Moreover, autophagy and AMPK phosphorylation in PTECs were reduced. These phenotypes were partially reversed in D-gal-induced Cav1 knockout mice. Similar results were observed in D-gal-induced human proximal tubular epithelial (HK-2) cells, but these effects were blocked when AMPK activation was inhibited. Additionally, in CaMKK2 knockdown HK-2 cells, si CAV1 failed to promote AMPK phosphorylation, whereas this effect persisted when STK11 was knocked down. Besides, we examined the phosphorylation of CaMKK2 and found that si CAV1 increased its activity. Given that CaMKK2 activity is affected by intracellular Ca 2+ , we examined Ca 2+ levels in HK-2 cells and found that D-gal treatment reduced intracellular Ca 2+ concentration, but CAV1 knockdown did not alter these levels. Through GST pull-down assays, we demonstrated a direct interaction between CAV1 and CaMKK2. In conclusion, these findings suggest that CAV1 exacerbates renal tubular epithelial cell senescence by directly interacting with CaMKK2, suppressing its activity and AMPK-mediated autophagy via a Ca 2+ -independent pathway.

    CELLULAR AND MOLECULAR LIFE SCIENCES IF:6.2

    N6-methyladenosine (m6A) modification, a dynamically reversible epigenetic mechanism, is implicated in pulmonary fibrosis (PF) progression. The function and molecular mechanisms of m6A reader, insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) in PF remain elusive. This study investigates the mechanistic contributions of IGF2BP1 to PF development. We found IGF2BP1 was overexpressed in macrophages of PF mice. IGF2BP1 knockdown markedly attenuated bleomycin (BLM)-induced lung pathology, as evidenced by reduced inflammatory cell infiltration, fibroblast accumulation, Ashcroft fibrosis scores, and hydroxyproline deposition. Furthermore, IGF2BP1 knockdown downregulated PF-associated markers in lung tissues and embryonic lung fibroblasts (ELFs), including TGF-β1, α-SMA, Collagen-I/III, Arg1, CCL18, Ym1, CD163, IL-6, IL-1β, and TIMP1, while decreasing the CD68 + /CD163 + macrophage proportion. Mechanistic studies revealed that IGF2BP1 bound to and stabilized thrombospondin-1 (THBS1) in an m6A-dependent manner. THBS1 overexpression rescued the suppression of macrophage M2 polarization caused by IGF2BP1 knockdown. Additionally, THBS1 overexpression counteracted IGF2BP1 knockdown-mediated inhibition of glycolysis, restoring HK2, LDHA, and PKM2 expression, lactate/glucose metabolism, and ATP production. Intriguingly, THBS1 physically interacted with toll-like receptor 4 (TLR4), and TLR4 overexpression reversed the inhibitory effect of THBS1 knockdown on macrophage M2 polarization and glycolytic reprogramming. Collectively, our findings demonstrate that IGF2BP1 drives PF progression by stabilizing THBS1 mRNA via m6A modification, thereby promoting TLR4-mediated macrophage M2 polarization and glycolytic activation. This study unveils a novel IGF2BP1/THBS1/TLR4 regulatory axis in PF pathogenesis, offering potential therapeutic targets.

    Journal of Translational Medicine IF:6.1

    Background THOC7-AS1 and FSTL1 expression are frequently upregulated in cutaneous squamous cell carcinoma (cSCC). However, their molecular biological mechanisms remain elusive and their potential as therapeutic targets needs urgent exploration.Methods Human tissue samples were used to evaluate clinical parameters. In vitro and in vivo experiments assessed biological functions. Quantitative PCR, western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, RNA fluorescence in situ hybridization, RNA pull-down, RNA immunoprecipitation, silver staining, chromatin immunoprecipitation, dual luciferase reporter assays etc. were utilized to explore the molecular biological mechanisms.Results We found FSTL1 is an oncogene in cSCC, with high expression in tumor tissues and cells. Its elevated expression closely associates with tumor size and local tissue infiltration. In vitro and in vivo, high FSTL1 expression promotes cSCC proliferation, migration and invasion, facilitating malignant behaviors. Mechanistically, FSTL1 interacts with ZEB1 to promote epithelial-to-mesenchymal transition (EMT) in cSCC cells. Exploring upstream regulation, we found THOC7-AS1 can interact with OCT1, which binds the FSTL1 promoter region and promotes FSTL1 expression, facilitating cSCC progression. Finally, treating tumors with THOC7-AS1 antisense oligonucleotides inhibited cSCC proliferative and migratory abilities, delaying tumor progression.Conclusion sThe THOC7-AS1/OCT1/FSTL1 axis regulates EMT and promotes tumor progression in cSCC. This study provides clues and ideas for cSCC targeted therapy.

    Frontiers in Pharmacology IF:4.8

    Background: Intervertebral disc degeneration (IDD) significantly contributes to low back pain (LBP), yet effective treatment options are scarce. BSHXF, a classical traditional Chinese medicine formula, demonstrates dual pharmacological actions: tonifying kidneys, strengthening bones, activating blood circulation, and resolving stasis. It has been widely used in IDD management. Given its potential, combining BSHXF with miRNA regulation and stem cell therapy may enhance therapeutic outcomes by targeting molecular and cellular pathways underlying IDD pathogenesis.Aim of the study: IDD is recognized as one of the primary causes of low back pain, yet effective therapeutic interventions for this condition remain limited. This study explores the role of BSHXF drug-containing serum combined with adipose-derived stem cells (ADSCs) in slowing IDD progression via the miR-199a-3p/TGF-β/Smad signaling pathway. By comprehensively investigating the synergistic effects of this combination therapy, we aim to propose a novel multi-target strategy that addresses the complex pathogenesis of IDD.Materials and Methods: This study employed a combination of in vivo and in vitro models. An IDD model was induced in rat caudal intervertebral discs through needle puncture, while an oxidative stress-induced ADSCs injury model was created in vitro using tert-butyl hydroperoxide (T-BHP). Cell viability was measured with the CCK-8 assay. Cell cycle distribution and mitochondrial reactive oxygen species (ROS) levels were assessed using flow cytometry. Cellular senescence was assessed using SA-β-galactosidase staining. Lactate dehydrogenase (LDH) activity was quantified to evaluate cellular damage. Differentiation into nucleus pulposus-like cells was assessed using immunofluorescence double staining for CD73 and COL2A1. ELISA was used to measure inflammatory cytokines (TNF-α, IL-1β, IL-4, IL-10) in cell supernatants. miR-199a-3p expression was determined using RT-qPCR. Western blotting was employed to quantify COL2A1, SOX9, and ACAN protein levels, reflecting nucleus pulposus-like differentiation and extracellular matrix (ECM) synthesis capacity. Western blotting was employed to assess pathway activity by analyzing the protein expressions of TGF-β1, Smad2, Smad3, and their phosphorylated forms, P-Smad2 and P-Smad3. In vivo experiments assessed histopathological degeneration through hematoxylin-eosin (HE) and Safranin O-Fast Green staining. Immunohistochemistry (IHC) analyzed COL1A1 and COL2A1 expression levels. RT-qPCR quantified miR-199a-3p expression. Western blotting was employed to assess the expression levels of TGF-β1, Smad2, Smad3, P-Smad2, and P-Smad3 for pathway regulation evaluation.Results: Our experimental results demonstrated that serum containing BSHXF significantly alleviated T-BHP-induced oxidative stress, improved the cellular microenvironment, promoted ADSCs proliferation, and decelerated cellular senescence. Further mechanistic analysis revealed that BSHXF significantly activated the TGF-β/Smad signaling pathway, driving the differentiation of ADSCs into nucleus pulposus-like cells and restoring normal cell cycle progression. Overexpression of miR-199a-3p inhibited the TGF-β/Smad pathway, leading to ECM degradation and elevated expression of inflammatory factors (TNF-α, IL-1β). In contrast, BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression. In vivo experiments demonstrated that miR-199a-3p overexpression exacerbated IDD, characterized by reduced COL2A1 expression, elevated COL1A1 levels, and increased disc fibrosis. BSHXF intervention markedly attenuated IDD progression by downregulating miR-199a-3p expression, reducing disc fibrosis, and effectively restoring collagen expression.Conclusion: BSHXF activated the TGF-β/Smad pathway to promote the differentiation of ADSCs into nucleus pulposus-like cells. It exerted protective effects by alleviating oxidative stress damage, improving the microenvironment, delaying senescence, and enhancing cellular functions. This study is the first to reveal that miR-199a-3p overexpression exacerbates intervertebral disc fibrosis and degeneration. BSHXF restored TGF-β/Smad pathway activity by downregulating miR-199a-3p expression, thereby improving disc structure and function. This integrated approach offers a novel multi-target intervention strategy for IDD, demonstrating significant therapeutic potential.

    INTERNATIONAL IMMUNOPHARMACOLOGY IF:4.7

    Biofilm formation in Mycobacterium tuberculosis (MTB) enhances antibiotic resistance by impeding drug penetration and evading host immunity. This poses a significant challenge to conventional drug therapies, highlighting the urgent need for novel treatment strategies to overcome MTB's biofilm-mediated resistance. This study introduces the development of low-intensity ultrasound-mediated levofloxacin (LEV) and catalase (CAT) -loaded PEG-PLGA nanoparticles (LEV@CAT-NPs) for antimicrobial sonodynamic therapy (aSDT), offering an innovative strategy to combat BCG biofilm infection, by utilizing BCG as a model for MTB. N -acetylcysteine (NAC) was supplemented during the latter stages of the treatment process of anti-infection therapy to facilitate the transformation of macrophages to the M2 phenotype and to promote tissue repair. Ultrasound-mediated LEV@CAT-NPs, along with the subsequent addition of NAC not only enhanced repair at the infection site but also led to a progressive resolution of the inflammatory response in tissues. The treatment regimen induced a shift in macrophage polarization towards the M2 phenotype and modulated cytokine expression, decreasing pro-inflammatory while increasing anti-inflammatory cytokines, which contributed to the restoration of redox balance in the infected tissues. This study proposes a novel therapeutic strategy that not only targets drug-resistant MTB but also promotes tissue repair, highlighting its dual role in infection management.

    MEDIATORS OF INFLAMMATION IF:4.2

    Background Bone fracture healing is a multifaceted process that involves different stages and intercellular interactions. In this study, we aimed to investigate the effect of Taohong Siwu decoction (TSD) on bone fracture healing and the underlying mechanisms. Methods First, a mouse model of femur fracture was constructed, and TSD intervention was administered for durations of 7, 14, and 21 days. Following this, immunofluorescence (IF) was employed to evaluate the expression of CD90 (a marker for mesenchymal stem cells [MSCs]), endomucin (Emcn), and CD31. We also treated MSCs with normal serum and 10% TSD-containing serum to investigate the effects of TSD. Molecular docking was applied to verify the binding of active compounds in TSD to pVon Hippel–Lindau (VHL). Additionally, MSCs were treated with paeoniflorin and 2-methoxyestradiol (2-ME2) to explore the effects of paeoniflorin. Subsequently, mouse aortic endothelial cells were extracted and identified. Furthermore, normally cultured MSCs were cocultured with endothelial cells. MSCs were exposed to control serum, 10% TSD-containing serum, and a combination of 10% TSD-containing serum with 2-ME2. Finally, we administered a combination of 2-ME2 over 21 days to evaluate its effects on the fractured mice. Results TSD significantly influenced H-type angiogenesis during the healing process of fractured mice. Compared to the sham group, the model group exhibited lower levels of Emcn, CD90, hypoxia-inducible factor-1 alpha (HIF-1α), and vascular endothelial growth factor (VEGF), while there was an increase in pVHL expression. After 7, 14, and 21 days of TSD intervention, the levels of Emcn, CD90, HIF-1α, VEGF, and pVHL gradually increased, whereas HIF-1α expression decreased. In vitro experiments revealed that TSD enhanced the proliferation and migration of MSCs while inhibiting the ubiquitination of pVHL/HIF-1α. Moreover, ferulic acid, amygdalin, hydroxysafflor yellow A, and paeoniflorin demonstrated a strong affinity for binding with pVHL. Notably, paeoniflorin promoted the proliferation and migration of MSCs through the pVHL/HIF-1α pathway to promote angiogenesis. Furthermore, TSD was found to enhance endothelial angiogenesis in MSCs. In summary, TSD affects H-type angiogenesis and MSCs homing during the healing process of fractured mice through the HIF-1α axis. Conclusions TSD regulated MSC-mediated H-type angiogenesis to accelerate fracture healing through VHL/HIF-1α ubiquitination.

    Arab Journal of Gastroenterology IF:1.1

    Background and study aims Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition worldwide. Although forkhead box O4 (FOXO4) is implicated in liver diseases, its role in NAFLD remains unclear. Material and methods FOXO4 knockout mice were generated using CRISPR/Cas9 and fed a normal or high-fat diet (NFD/HFD). Human hepatic stellate cell line (LX-2) cells were transfected in vitro with a FOXO4 siRNA plasmid. Results Twelve weeks of HFD feeding downregulated FOXO4 expression and reduced its colocalization with hepatocyte nuclear factor 4α (HNF4α). HFD-fed mice exhibited increased liver-to-body weight ratios; marked lipid/glycogen accumulation; and elevated serum alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglyceride, and nonesterified fatty acid levels. These pathological manifestations were further exacerbated upon genetic ablation of FOXO4. Specifically, FOXO4 knockout aggravated HFD-induced upregulation of α-smooth muscle actin protein; increased the expression of profibrotic genes (including collagen type I alpha 1 chain, transforming growth factor-β1, and tissue inhibitor of metalloproteinases 1) and inflammatory mediators (such as interleukin-1β, IL-6, and tumour necrosis factor-α); and increased hepatocyte apoptosis. Mechanistically, FOXO4 suppressed secreted phosphoprotein 1 (SPP1) expression in LX-2 cells via direct binding to the SPP1 promoter and transcriptional suppression of its activity. Conclusion FOXO4 downregulation exacerbates HFD-induced NAFLD progression via SPP1-dependent steatosis, inflammation, and fibrosis, thereby suggesting its potential as a therapeutic target.

    复制成功!

    内容已复制到剪贴板

    在线客服
    关闭
    小薇 薇薇 小艾 小奥
    联系销售
    技术支持

    image.png

    月琴艾碧维二维码.jpg